The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Telomere length as a prognostic tool in CLL: is FCR chemoimmunotherapy the right treatment?
Telomere length has been shown to be a powerful predictor of outcome following fludarabine, cyclophosphamide and rituximab (FCR)-based treatment in chronic lymphocytic leukemia (CLL). Christopher Fegan, MB, MD, FRCP, FRCPath, of Cardiff University, Cardiff, UK, explains how this knowledge has the potential to identify patients who would benefit from FCR-based chemoimmunotherapy and those who would not. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. Fegan discusses how this data removes the unknown.
